---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274612"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:39:38.696674+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Five MACs classify Sight Sciences' OMNI procedures as investigational; 63% of revenue at risk

## Summary
- Four new MACs (Palmetto, Celerian, NGS, Noridian) plus prior WPS LCD classify OMNI canaloplasty/trabeculotomy as investigational, effective Dec 24, 2023.
- The five MACs cover states representing ~63% of Sight Sciences' 2022 Surgical Glaucoma revenue.
- LCDs trigger 'Reimbursement Trigger Event' under MidCap credit agreement; monthly principal payments begin Jan 2024.
- If LCDs take effect, company may breach revenue covenant in 2024, allowing lender to accelerate repayment of $35M term loan.
- Company plans to engage MACs and CMS to delay or reconsider; intends to pursue reconsideration if implemented.

## SEC filing metadata
- accession: 0001193125-23-274612
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000119312523274612/0001193125-23-274612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000119312523274612/d393470d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274612
- JSON: https://secwatch.observer/filing/0001193125-23-274612.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274612.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.